Welcome to our dedicated page for Xencor news (Ticker: XNCR), a resource for investors and traders seeking the latest updates and insights on Xencor stock.
Xencor, Inc. (XNCR) is a clinical-stage biopharmaceutical leader pioneering engineered antibody therapeutics for cancer and autoimmune diseases through its proprietary XmAb® technology platform. This page serves as the definitive source for tracking Xencor's latest developments, providing investors and industry observers with timely updates on scientific advancements and business milestones.
Access comprehensive coverage of Xencor's clinical trial progress, regulatory updates, and strategic collaborations with global pharmaceutical partners. Our curated news collection features verified press releases and analysis-worthy developments including technology licensing agreements, pipeline expansions, and research breakthroughs in antibody engineering.
Key content focuses include updates on XmAb® platform innovations, partnership announcements with major drug developers, clinical study results for novel cancer treatments, and progress in autoimmune therapy candidates. All content is rigorously vetted to ensure relevance to investment decision-making and scientific credibility.
Bookmark this page for streamlined access to Xencor's evolving story in biotherapeutic innovation. Check regularly for critical updates on therapeutic candidates moving through clinical development phases and new applications of its protein engineering expertise.
Xencor (NASDAQ: XNCR) announced it will regain exclusive worldwide rights to plamotamab, a CD20 x CD3 bispecific T-cell engager, after Janssen Biotech terminated its rights under their collaboration agreement. Xencor had advanced plamotamab through Phase 1 clinical trials targeting hematologic cancers. Despite Janssen's withdrawal, it retains rights to develop and commercialize other B-cell targeting CD28 bispecific antibodies, JNJ-9401 and JNJ-1493, which are in Phase 1 clinical trials for prostate cancer and B-cell malignancies respectively.
Xencor emphasizes that plamotamab is Phase 2 ready and subcutaneously administered, highlighting its potential to address unmet medical needs. The company remains eligible for milestone payments and royalties from Janssen's ongoing projects and has the option to co-fund development costs for increased royalty benefits.
Xencor, a clinical-stage biopharmaceutical company, reported financial results for the first quarter ended March 31, 2024, focusing on bispecific T cell engagers for cancer treatment. Recent highlights include the advancement of multiple oncology programs, FDA approval of Ultomiris, and positive results in malaria prevention. The company appointed a new CFO and provided financial guidance with a cash balance of $646.7 million as of March 31, 2024. Despite a decrease in revenues and an increased net loss compared to the previous year, Xencor remains well-funded.
FAQ
What is the current stock price of Xencor (XNCR)?
What is the market cap of Xencor (XNCR)?
